Case report of orbital violation with placement of ethmoid drug‐eluting stent

Villari, Craig R.; Wojno, Ted; DelGaudio, John M.

doi:10.1002/alr.20091

Cited by 15 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1312,1313 There has also been a case report of orbital violation leading to pain and a permanently dilated pupil. 1314 Biodegradable drug-eluting stents offer the benefit of having both a mechanical spacer combined with precise sustained release of medication into the sinus cavity over a known period of time. 1315 Unlike nonbiodegradable stents, they may not require potentially painful postoperative removal.…”

Section: Xd6 Surgical Principles/techniques: Drug Eluting Packingmentioning

confidence: 99%

International Consensus Statement on Allergy and Rhinology: Rhinosinusitis

Orlandi

Kingdom

Hwang

et al. 2016

Int Forum Allergy Rhinol

557

888

View full text Add to dashboard Cite

Background:The body of knowledge regarding rhinosinusitis (RS) continues to expand, with rapid growth in number of publications, yet substantial variability in the quality of those presentations. In an effort to both consolidate and critically appraise this information, rhinologic experts from around the world have produced the International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR:RS). Methods:Evidence-based reviews with recommendations (EBRRs) were developed for scores of topics, using previously reported methodology. Where existing evidence was insufficient for an EBRR, an evidence-based review (EBR) was produced. The sections were then synthesized and the entire manuscript was then reviewed by all authors for consensus. Results:The resulting ICAR:RS document addresses multiple topics in RS, including acute RS (ARS), chronic RS (CRS) with and without nasal polyps (CRSwNP and CRSsNP), recurrent acute RS (RARS), acute exacerbation of CRS (AE-CRS), and pediatric RS. Conclusion:As a critical review of the RS literature, ICAR:RS provides a thorough review of pathophysiology and evidence-based recommendations for medical and surgical treatment. It also demonstrates the significant gaps in our understanding of the pathophysiology and optimal management of RS. Too o en the foundation upon which these recommendations are based is comprised of lowerlevel evidence. It is our hope that this summary of the evidence in RS will point out where additional research efforts may be directed. C 2016 ARS-AAOA, LLC. Key Words:rhinosinusitis; chronic rhinosinusitis; acute rhinosinusitis; recurrent acute rhinosinusitis; evidence-based medicine; systematic review; endoscopic sinus surgery List of Abbreviations Used

show abstract

Section: Xd6 Surgical Principles/techniques: Drug Eluting Packingmentioning

confidence: 99%

International Consensus Statement on Allergy and Rhinology: Rhinosinusitis

Orlandi

Kingdom

Hwang

et al. 2016

Int Forum Allergy Rhinol

557

888

View full text Add to dashboard Cite

show abstract

“…Despite the eventual removal of the device, the patient's pupil remained dilated in the affected eye. 3 …”

Section: Discussionmentioning

confidence: 99%

Retained Drug-eluting Stents and Recalcitrant Chronic Rhinosinusitis: A Case Report

Sjogren

Parker

Boyer

2013

Allergy�Rhinol (Providence)

View full text Add to dashboard Cite

Corticosteroids are the mainstay of treatment for refractory chronic rhinosinusitis. The off-label use of steroid-eluting stents has increasingly gained popularity in functional endoscopic sinus surgery for decreasing postoperative inflammation and synechiae formation. However, there is a paucity of data outlining the safety profile of this device despite its widespread use. This study was designed to report a newly described complication of retained drug-eluting stents from endoscopic sinus surgery for refractory rhinosinusitis. This report highlights a potential risk of the drug-eluting stent in the treatment of recalcitrant rhinosinusitis and the need for further clinical investigations whenever a novel medical device becomes available on the market.

show abstract

“…The SEI also compares favourably when assessing improvement in patient symptoms (a -29.7 change in baseline RSDI score using the Propel implant [25] compared with a change of -19.1 in other studies not using an SEI) [31]. Villari et al [32] reported a case of orbital violation due to a Strutus Ethmoid nonabsorbable sinus implant (Acclarent, Inc., Menlo Park, California, USA) resulting in severe orbital pain and a permanently dilated pupil. Occasional complications have been reported from the use of other sinus implants.…”

Section: Key Pointsmentioning

confidence: 99%